June 12 – 17, 2022
Sitges, Spain
| Chairs: | Tarit Mukhopadhyay, Merck Research Laboratories, USA |
|---|---|
| Charles Lutsch, Sanofi Pasteur, France | |
| Linda Hwee-Lin Lua, University of Queensland, Australia | |
| Francesc Godia, Universitat Autònoma de Barcelona, Spain |
The articles for these proceedings are not peer-reviewed.
Users who click the Follow button on a series will receive a weekly email (sent on Wednesdays) listing new additions that have been published to that series. A user's multiple follows are combined into a single email, so the email will include new additions for each thing being followed. Through the “Follow Management” link on the My Account page, users can see what they are following and can un-follow anything they no longer want to follow.
Conference Program, Francesc Godia, Linda Hwee-Lin Lua, Charles Lutsch, and Tarit Mukhopadhyay (Article)
A tale of two worlds from the ongoing pandemic – unprecedented successes and all too familiar failures, David Robinson (Abstract)
Advances in therapeutic HIV vaccine development, Christian Brander (Abstract and Presentation)
SARS-CoV-2 and Ebola: CHO-based manufacturing provides high quality subunit-vaccine candidates and diagnostics, Paco Pino (Abstract)
Microarray patch delivery of un-adjuvanted influenza vaccine induces potent and broad-spectrum immune responses in a phase I clinical trial, Alexandra C. I. Depelsenaire, Angus H. Forster, Katey Witham, Margaret Veitch, James W. Wells, Christopher D. Anderson, Adam Wheatley, Melinda Pryor, Jason D. Lickliter, Barbara Francis, Steve Rockman, Jesse Bodle, Peter Treasure, Julian Hickling, and Germain J. P. Fernando (Abstract)
Development of a thermostable, multivalent filovirus vaccine based on recombinant subunit proteins, Axel T. Lehrer, Teri-Ann S. Wong, Michael M. Lieberman, Chih-Yun Lai, Eleanore Chuang, David Clements, Jaime Horton, Oreola Donini, Theodore W. Randolph, Kendall B. Preston, Liana O. Medina, and Thomas W. Geisbert (Abstract)
The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNA vaccines, Juan Manuel Carreño, Ariel Raskin, Gagandeep Singh, Johnstone Tcheou, Hisaaki Kawabata, Charles Gleason, Komal Srivastava, Vladimir Vigdorovich, Nicholas Dambrauskas, Sneh Lata Gupta, Irene Gonzalez, Jose Luis Martinez, Stefan Slamanig, D. Noah Sather, Rama Raghunandan, Ponthip Wirachwong, Sant Muangnoicharoen, Punnee Pitisuttithum, Jens Wrammert, Mehul S. Suthar, Weina Sun, Peter Palese, Adolfo Garcia-Sastre, Viviana Simon, and Florian Krammer (Abstract)
Targeting endogenous retroviruses using a novel adenoviral vaccine technology, Anne-Marie Andersson, Emeline Ragonnaud, Joana D. Boluña, Isabella S. Pedersen, Amaia V. Bermejo, Lasse Neukirch, Karen N. Nielsen, Silke Schroedel, Christian Thirion, and Peter J. Holst (Abstract)
Rapid and high yield microbial protein production system for human and animal vaccines: C1 Filamentous fungus Thermothelomyces heterothallica, Noelia Valbuena (Abstract)
Superior SARS-CoV-2 RBD antigen designs for highly specific, quantitative serotests, Miriam Klausberger, Mark Dürkop, Nikolaus Kienzl, Gerhard Stadlmayr, Lukas Mach, Gordana Wozniak-Knopp, and Reingard Grabherr (Abstract)
Learnings from the development of Covid-19 vaccines, Kathrin Jansen (Abstract)
Workshop: Innovation in Global Health, Birgitte Giersing and Marion Menozzi-Amaud (Abstract and Presentation)
Discovery & Development of Therapeutic Interfering Particles (TIPs): single-administration SARS-CoV-2 and HIV antivirals with high barriers to the evolution of resistance, Leor Weinberg (Abstract)
Towards a platform process for the manufacture of glycoconjugate vaccines for pneumococcal disease, Dr. Michael Sulu, Neha Patel, Dr. Emily Kay, Dr. Jon Cuccui, and Dr. Frank Baganz (Abstract)
Enabling technologies for manufacturing thermostable and cost-effective vaccines, Justin Stanbro, Akhilesh Bhambhani, Morrisa Jones, Donna Williams, Jeffrey T. Blue, and Tarit Mukhopadhyay (Abstract)
Genomics of Vero cells: Understanding this cell line and its virus-host interactions for improved vaccine production, Marie-Angelique Sene,; Sascha Kiesslich; Haig Djambazian; Ioannis Ragoussis; Yu Xia; and Amine A. Kamen (Abstract)
From genome to structure and beyond, Mariagrazia Pizza (Abstract)
Production of influenza A virus defective interfering particles in a high cell density perfusion cultivation with continuous virus harvesting, Marc D. Hein, Anshika Chawla, Prerna Arora, Maurizio Cattaneo, Michael Winkler, Stefan Pöhlmann, Klaus Schughart, Yvonne Genzel, Sascha Y. Kupke, and Udo Reichl (Abstract)
Development of an automated microscale platform for conjugate vaccine production in E. coli, Jasmin J. Samaras and Martina Micheletti (Abstract)
Development of a purification process for HIV-1 VLPs, from supernatant to lyophilization, Elianet Lorenzo Romero, Laia Miranda, Irene González-Domínguez, Francesc Gòdia, and Laura Cervera (Abstract and Presentation)
AMBR®250 HT System: A key process development tool for new live virus and microbial vaccine candidates, Jessica Olson, Greeshma Manomohan, Alyssa Brown, Christopher Lee, Samantha Moyer, and Marc Wenger (Abstract and Presentation)
Increasing of PK15 biomass for PCV viral antigen production using modelbased and media optimization strategies that consider cellular metabolic requirements, Ziomara Gerdtzen, Felipe Véliz, Gerardo Flores, Felipe Sánchez, Andrea Villanueva, Kurt Pohlhammer, Daniel Morales, J. Cristian Salgado, Iván Valdés, Harold Oliva, and Samuel Valdevenito (Abstract)
Accelerating and intensifying manufacturing to enable large-scale supply of a new adenovirus-vectored vaccine within 100 days, Sandy Douglas, Alexander D Douglas, Carina C D Joe, Rameswara R Segireddy, Adam Berg, Yuanyuan Li, Dimitrio Doultsinos, Cathy Oliveira, Asma Ahmad, Nitin Chopra, Steffi Scholze, Piergiuseppe Nestola, and Julia Niemann (Abstract and Presentation)
Driving change in dtap batch release testing, Isabelle Bekeredjian-Ding, Bärbel Friedrichs, Walter Matheis, Björn Becker, Christel Kamp, Olga Ticha, and Volker Öppling (Abstract)
The implication of glycans on the ACE2: SARS-CoV-2 spike interaction, Manuel Reithofer, Rong Zhu, Yoo Jin Oh, Reingard Grabherr, Peter Hinterdorfer, and Miriam Klausberger (Abstract)
Generation of an international standard serum to measure influenza virus hemagglutinin stalk-reactive antibodies, Juan Manuel Carreno Quiroz, Tara Hurst, Raffael Nachbagauer, Mohammad Amin Behzadi, Shirin Strohmeier, Lynda Coughlan, Othmar Engelhardt, and Florian Krammer (Abstract)
New insights in formaldehyde-induced detoxification of the tetanus toxin: Chemical modification stoichiometry and characterization of intra- and inter-molecular cross-links, Thierry Eynard, Sébastien Peronin, Amaud Salvador, Fabien Barbirato, Vincent Colombie, Céline Rocca, Nour Al Turihi, Catherine Jourdat, and Jérôme Lemoine (Abstract)
Development of analytical characterization tools for process monitoring of adenovirus-based vaccines (ChAdOx and Ad5), Shaleem I. Jacob, John M. Hickey, Andrew Tait, Fatemeh Dastjerdi Vahid, Sarah Rouse, Joseph Barritt, Alexander Douglas, Sangeeta B. Joshi, David B. Volkin, and Daniel G. Bracewell (Abstract)
Advances in bioprocessing, analytics and formulation of influenza HA-VLP vaccine candidates produced by insect cells, António Roldão, Ricardo Correia, Bárbara Fernandes, Sofia B. Carvalho, Ricardo J. S. Silva, and Cristina Peixoto (Abstract)
On-Line influenza virus quantification for viral production processes thanks to affinity-based surface plasmon resonance biosensor, Emma Petiot, Laurent Durous, Manuel Rosa-Calatrava, and Christophe A. Marquette (Abstract)
All doses are not the same: Potential role of vaccine quality in vaccine adverse reactions, Bruce Yu, Katharine T. Briggs, and Marc B. Taraban (Abstract and Presentation)
Development of the Oxford AstaZeneca Covid Vaccine, Sarah Gilbert (Abstract)
Developing a ‘One Health’ Nipah virus vaccine to protect animal and public health, Simon P. Graham (Abstract)
Design of mimotopes of a conserved epitope in dengue and Zika viruses for the obtention of broadly neutralizing antibodies, Esmeralda Cuevas-Juárez, Arturo Liñan, Carolina Hernandez, Mykhailo Kopylov, and Laura A. Palomares (Abstract)
Adenovirus-based vaccine platform for mucosal or parenteral immunization of chickens, Omar Famos Villar (Abstract)
Challenges and opportunities to formulate and stabilize vaccine candidates targeted for use in LMICs, David Volkin (Abstract and Presentation)
Development of an oral protein subunit COVID-19 vaccine to induce mucosal and systemic immune response, Elodie Burlet, Nissy Thomas, Shanna Carwell, Brett Gershman, and Garry Morefield (Abstract)
Development of a pneumococcal conjugate vaccine drug product: Ensuring stability, a robust manufacturing process and long-term commercial sustainability, William Smith (Abstract)
Development of a pentavalent Group B Streptococcus (GBS) glycoconjugate vaccine in Africa, Matthew Williams, Ebrahim Mohamed, Patrick Tippoo, and Seanette Wilson (Abstract and Presentation)
Disease X development and 100 days initiative, Nicolas Havelange (Abstract and Presentation)
Innovative facility options in a new era of urgent capacity needs, Thomas Hauser (Abstract)
A rapid response vaccine manufacturing platform as a countermeasure to epidemic threats, Tania Pereira Chilima and Héla Kallel (Abstract)
Advancing vaccine development and manufacture in Africa, Ebrahim Mohamed and Patrick Tippoo (Abstract and Presentation)
Test tubes and turnaround times: An accelerated biosafety testing approach for new vaccines against emerging pathogens, Sarah Sheridan (Abstract)
Production of high-quality SARS-CoV-2 antigens for vaccine development and serological assays implementation, Bárbara Fernandes, Rute Castro, Patricia Gomes-Alves, Mario Amacker, Toon Stegmann, Sylvain Fleury, Paula M. Alves, and António Roldão (Abstract)
Shifting the paradigm from global to national: innovative approaches for sustainable production of priority vaccines, Birgitte Giersing (Abstract)
Sterile filtration of large biomolecules - New insights using live attenuated vaccines and model particle suspensions, Adam Kristopeit, Wanli Ma, Sheng-ching Wang, Neil Taylor, and Andrew Zydney (Abstract and Presentation)
Production of influenza virus-like particles by insect cells and removal of baculovirus from virus-like particles and other extracellular vesicles, Alois Jungbauer, Katrin Reiter, Patricia Aguilar, Miriam Klausberger, Florian Strobl, Wolfgang Ernst, Gerald Striedner, and Reingard Grabherr (Abstract)
Chromatographic tools for optimization of IVT reaction and improving mRNA purification process, Amélie Boulais, Rok Sekimik, Kristina S. Nemec, Janja Skok, Klemen Božič, Anže Martinčič Celjar, Pete Gagnon, and Aleš Štrancar (Abstract)
High Density HEK293T culture for high yield, high quality, stable adenoviral vector production in Ambr® 250 stirred tank reactors, Amélie Boulais, Lara Nascimento-Brooks, Shuangqing Yu, Zhicheng Cao, Li Hu, Shuren Feng, Jinlu Du, Cuiling Song, and Junjie Luo (Abstract)
Unveiling process knowledge for plasmid DNA fermentation across upstream scales, Amélie Boulais and Lara Nascimento-Brooks (Abstract)
Use of sulfated-cellulose membrane adsorbers to intensify purification of cell culturederived influenza A and B viruses, Amélie Boulais, Ricarda Busse, and A. Raquel Fortuna (Abstract)
Development of scalable downstream processing platform for HEK293SF cell-based influenza vaccine production, Amine Kamen, Xingge Xu, Zeyu Yang, Irene González Domínguez, Cécile Toussaint, Alice Bernier, Alina Venereo Sanchez, Omar Famos, and Cristina Aglaia Alves Tottoli e Silva (Abstract)
Multivalent Influenza vaccine production in HEK-293 cells in response to pandemic threats, Amine Kamen, Cécile Toussaint, Omar Farnos, David Sharon, Alina Venereo-Sanchez, Irene González-Domínguez, Alice Bernier, Xingge Xu, and Hanan Chaabane (Abstract)
The next generation of fibroblast-based vaccine development, Anna-Barbara Hachmann, Megan Pajak-Lee, David Klinkenberg, Andrew M. Campbell, Aneg L. Cortes, and Isabel M. Gimeno (Abstract)
Optimization, production, purification and characterization of HIV-1 Gag VLPs functionalized with SARS-CoV-2 Spike glycoprotein, Amau Boix-Besora, Elianet Lorenzo, Jesus Lavado-Garcia, Francesc Gòdia, and Laura Cervera (Abstract)
Rotavirus VP6 nanotubes show an antigen form-dependent adjuvant activity: Zika virus envelope protein monomer vs Zika virus-like particles, Arturo Liñan, Ana Ruth Pastor, Selene J. Uribe-Romero, Mabel Rodriguez, Octavio T. Ramirez, and Laura A. Palomares (Abstract)
Immunogenicity and efficacy of non-adjuvant tissue culture-based rabies vaccine produced in Ethiopia, Birhanu Hurisa, A Mengesha, G Kebede, A Godana, A Adhanom, S Kerga, D Nigussie, H Lemma, A Kebede, B Newayesiliasie, G Gebrewold, D Bankovskiy, A Metlin, and K Urga (Abstract)
Tackling a capacity bottleneck to permit large-scale downstream processing of an adenovirus-vectored vaccine, Carina Citra Dewi Joe, Thomas Linke, Piergiuseppe Nestola, Yuanyuan Li, Rameswara R. Segireddy, Richard Turner, and Alexander D. Douglas (Abstract)
Use of a parallel bioreactor scaledown system for optimisation of a perfusion-based upstream process for adenovirus production, Carina C.D. Joe, Steffi Scholze, Julia Niemann, and Alexander D. Douglas (Abstract)
Impact of Africa-based manufacturing on cost-per-dose: A theoretical, inside-out analysis, Casey Selwyn (Abstract)
Immune-profiling of innate and adaptive immunity following three vaccinations of the MERS vaccine candidate MVA-MERS-S, Christine Dahlke, Anahita Fathi, Leonie M. Weskamm, Bart L. Haagmans, Stephan Becker, Gerd Sutter, and Marylyn M. Addo (Abstract)
Accurate and precise viral quantification for rapid vaccine development in- process production monitoring using Radiance® Laser Force CytologyTM, Christof Hasse, Zachary L. Evans, Colin G. Hebert, and Sean J. Hart (Abstract)
Development of an innovative adenovirus-inspired self-assembling vaccine platform rapidly adaptable to coronaviruses and other emergent viruses, Christopher Chevillard, Axelle Amen, Solène Besson, Dalil Hannani, Isabelle Bally, Valentin Dettling, Salomé Gallet, Emilie Stermann, Guy Schoehn, Evelyne Gout, Daphna Fenel, Marlyse Buisson, Christophe Moreau, Pascal Poignard, Marie-Claire Dagher, and Pascal Fender (Abstract)
Decisional tools for successful commercialisation of novel vaccine technologies, Christos Stamatis, Tania D. Pereira Chilima, Jose Castillo, and Suzanne Fraid (Abstract)
Suspension Vero cell culture technology for high titer production of viral vaccines, Chun Fang Shen, Rénald Gilbert, Elodie Burney, Seyyed Mehdy Elahi, Stephane Lanthier, Amine Kamen, and Martin Loignon (Abstract)
Intensification of influenza virus production in fed-batch and perfusion cultures of HEK293SF cells, Cristina A.T. Silva, Amine A. Kamen, and Olivier Henry (Abstract)
The effect of the production method on the quality of coronavirus spike protein RBD variants of concern: Implications on the specificity and sensitivity of serological assays, Daniel Barreto, Michelle Gutiérrez, Fernando Losoya, Alberto Porras, Violeta Guadarrama, Vanessa Hernández, Dubhe Bulté, Laura A. Palomares, and Octavio T. Ramírez (Abstract)
Model-based process development for complex vaccine mixtures, Daphne Keulen, Roxana Disela, Geoffroy Geldhof, Olivier Le Bussy, Martin Pabst, and Marcel Ottens (Abstract)
Protein design and immunogenic analysis of COVID-19 vaccine candidates based on RBD/trimeric-spike antigens and chimeric VLPs antigens, Claudio Prieto, Ernesto Garay, Javier Villarraza, Antonela Fuselli, Agustina Gugliotta, Celeste Rodríguez, Victoria Gastaldi, Natalia Ceaglio, and Diego Fontana (Abstract)
RHABDO-LIKE RECOMBINANTE (VLPs), a novel veterinary rabies vaccine: Safety and efficacy trials in pets and cattle, Claudio Prieto, Diego Fontana, Federico Marsili, Ricardo Kratje, and Marina Etcheverrigaray (Abstract)
Rational design, expression and characterization of chimeric rabies VLPs displaying the major antigenic site of Foot and Mouth Disease Virus, Ernesto Garay, Diego Fontana, Lautaro Leschiutta, Ricardo Kratje, and Claudio Prieto (Abstract)
Process development for a flexible vaccine vector platform based on recombinant life virus, Dieter Palmberger,; Shirin Preinsperger; Willibald Steinfellner; Matthias Müllner; Alois Jungbauer; and Kerstin Rumpelmayr (Abstract)
Development of a universal group 2 influenza virus vaccine using chimeric hemagglutinin constructs, Eduard Puente-Massaguer, Madhumathi Loganathan, Weina Sun, Peter Palese, and Florian Krammer (Abstract)
Design of a vaccine against dengue and Zika viruses based on a mimotope of the envelope dimer epitope, Esmeralda Cuevas-Juárez, Arturo Liñan, Carolina Hernandez, Mykhailo Kopylov, Octavio T. Ramírez, and Laura A. Palomares (Abstract)
Design of mimotopes of a conserved epitope in dengue and Zika viruses for the obtention of broadly neutralizing antibodies, Esmeralda Cuevas-Juárez, Arturo Liñan, Carolina Hernandez, Mykhailo Kopylov, and Laura A. Palomares (Abstract)
Optimisation of an alkaline lysis process for a plug- and play plasmid DNA production, Fatma Almulla and Eli Keshavarz-Moore (Abstract)
Analytical development to support manufacturing of a sustainable vaccine against Invasive Nontyphoidal Salmonellosis, Francesca Necchi, Francesco Citiulo, Maria Grazia Aruta, Federico Pippi, Antonia De Felice, Alessandra Acquaviva, Emilia Cappelletti, Vittoria Marchetti, Danielle Carson, Sophie Myhill, Luigi Sollai, Carlo Giannelli, Daniele De Simone, Caroline Vipond, Omar Rossi, Francesco B. Scorza, Anna M. Colucci, and Rocio Canals (Abstract)
A universal Influenza B vaccine using mosaic-hemagglutinin vaccine candidates, Irene González-Domínguez, Yonghong Liu, Eduard Puente-Massaguer, Nicholas Lemus, Stefan Slamanig, Tsoi Ying Lai, Shirin Strohmeier, Madhumathi Loganathan, Jose Martínez-Guevara, Florian Krammer, Adolfo García-Sastre, Peter Palese, and Weina Sun (Abstract)
Differential glycosylation and extracellular vesicle biogenesis in HEK293 upon transient transfection, Jesús Lavado-García, Irene González-Domínguez, Laura Cervera, Inmaculada Jorge, Jesús Vázquez, Tao Zhang, Manfred Wuhrer, and Francesc Gòdia (Abstract)
This is our shot - new measures of vaccine infectivity, Johanna Bacher (Abstract)
Production and characterization of hepatitis B Virus-like Particles expressed in HEK293 and CHO-K1 recombinant cell lines. Analysis of the humoral immune response, Juan Manuel Battagliotti, Diego Fontana, Marina Etcheverrigaray, and Claudio Prieto (Abstract)
Vaccine manufacturing capacity expansion – An approach to meet global needs based on Covid-19 learnings, Julia Kuhn (Abstract and Presentation)
Biomanufacturing using single use systems: Case study of fluoropolymer material, Julien Muzard, Muhammad Siddiqui, and Ross Acucena (Abstract)
Overviews of vaccine technology for neglected diseases in developing Latin America country - Peru, Karen D. Calvay Sanchez, Yanina Zarate Sulca, and Giovanna Mendoza Mujica (Abstract)
Production of monoclonal antibodies specific to soluble proteins of Bartonella bacilliformis, Yanina Zarate Sulca, Yolanda Medina, Karen D. Calvay Sanchez, and Giovanna Mendonza Mujica (Abstract)
Maximizing viral titer yield at harvest through metabolic process analytical technology (PAT), Katherine Forrester, Marena Trauger, Thomas Randolph Blanda, and Neil Templeton (Abstract)
Affinity resins enable a multi-vaccine/platform purification process and rapid response to new viruses, Warren Kett and Kent Hallenbeck (Abstract)
A novel SARS-CoV-2 (T Cell) vaccine candidate designed using the iVAX platform, Kirk Haltaufderhyde, Christine M. Boyle, Andres H. Gutierrez, Mayara Grizotte-Lake, Frances Terry, Bethany G. McGonnigal, Nicole Ruggiero, Leonard Moise, William D. Martin, and Anne S. De Groot (Abstract)
Long-term propagation of influenza A virus and its defective interfering particles: Analyzing dynamic competition to select antiviral candidates, Lars Pelz, Daniel Rüdiger, Tanya Dogra, Fadi G. Alnaji, Yvonne Genzel, Christopher B. Brooke, Sascha Y. Kupke, and Udo Reichl (Abstract)
High cell density culture for VLP production in latent virus-free insect cell line, Lena Achleitner, Peter Satzer, and Alois Jungbauer (Abstract)
Novel purification strategies for Influenza neuraminidase-VLPs, Leticia Guzmán-Ruiz, Miriam Klausberger, Florian Krammer, Alois Jungbauer, and Reingard Grabherr (Abstract)
Intensified high yield production of GMMA based vaccines for high burden neglected disease, Luigi Sollai, Angela Daniele, Giulia Iannello, Federico Pippi, Antonia De Felice, Francesca Necchi, Rocio Cannals, Francesco Berlanda Scorza, and Anna Maria Colucci (Abstract)
Influence of DNA-protein interactions on purification and assembly of virus-like particles, Lukas Gerstweiler,; Jingxiu Bi; Linda Lua; and Anton Middelberg (Abstract)
Bioanalytical tools for the quantification of in-process and final product samples of a rotavirus vaccine, Sofia B. Carvalho, Mafalda M. Dias, Jean-Philippe Matheise, Guillaume Van Beersel, Isabelle Knott, Patrícia Gomes-Alves, and Paula M. Alves (Abstract)
A versatile capillary gel electrophoresis methodology for in-process and final product characterization of virus-based targets, Rita Fernandes, José Escandell, Filipa Moura, Ana C.L. Guerreiro, Sofia B. Carvalho, Tiago Q. Faria, Ricardo J.S. Silva, Patrícia Gomes-Alves, and Cristina Peixoto (Abstract)
Development of a new magnetic bead platform for use in GMP production of mRNA vaccines, Marie Bosnes, Nini U.H. Kjus, Christopher Stensrud, Elisabeth Breivold, Ausra Kaleckiene, Axl Neurauter, and Lene Aasveen (Abstract)
Biomanufacturing technology advances enable rapid response to disease outbreaks, Tania Pereira Chilima and Marie Jourdan (Abstract)
Improved Ad26 vaccine stability by mitigating interaction of viral particles with glass surfaces, Martinus Capelle, Olga Labovitiadi, and Joao Calado da Silva Freire (Abstract)
Development of a pentavalent Group B Streptococcus (GBS) glycoconjugate vaccine in Africa, Seanette Wilson, Ebrahim Mohamed, Patrick Tippoo, and Matthew Williams (Abstract)